FOLFOX-hepatic arterial infusion chemotherapy combined with programmed cell death receptor-1 inhibitor and targeted drug for treating China liver cancer staging stage Ⅲ a hepatocellular carcinoma
10.13929/j.issn.1672-8475.2024.07.003
- VernacularTitle:FOLFOX-肝动脉灌注化疗联合程序性死亡受体-1抑制剂和靶向药物治疗中国肝癌分期Ⅲa期肝细胞癌
- Author:
Di WU
1
;
Ziyi ZHU
;
Longfei FAN
;
Yulin TAN
Author Information
1. 蚌埠医科大学第一附属医院介入科,安徽 蚌埠 233000
- Keywords:
carcinoma,hepatocellular;
programmed cell death receptor-1;
chemotherapy,cancer,regional perfusion
- From:
Chinese Journal of Interventional Imaging and Therapy
2024;21(7):393-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the value of FOLFOX-hepatic arterial infusion chemotherapy(HAIC)combined with programmed cell death receptor-1(PD-1)inhibitor+targeted drug for treating China liver cancer staging(CNLC)stageⅢa hepatocellular carcinoma(HCC).Methods Sixty-one patients with CNLC stage Ⅲa HCC who underwent PD-1 inhibitor+targeted drug treatment were retrospectively enrolled and divided into observation group(n=30)and control group(n=31)based on whether received FOLFOX-HAIC treatment or not.The general information,treatment strategy,adverse reactions and therapeutic effects were compared between groups,and the value of treatment strategy in observation group was analyzed.Results No significant difference of general information nor PD-1 inhibitor+targeted drug strategy was found between groups(both P＞0.05).Among 1-2 grade adverse reactions,the incidence of nausea,vomiting and abdominal pain in observation group were higher than those in control group(both P＜0.05),while no significant difference of the other 1-2 grade nor 3 grade adverse reactions was observed(all P＞0.05).The objective response rate(ORR),progression free survival(PFS)and overall survival(OS)of observation group were all higher than those of control group(all P＜0.05).Conclusion FOLFOX-HAIC combined with PD-1 inhibitor+targeted drug was more effective for treating CNLC stage Ⅲa HCC with acceptable safety.
